Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder

Callie L. McGrath, BA; Mary E. Kelley, PhD; Paul E. Holtzheimer III, MD; Boadie W. Dunlop, MD; W. Edward Craighead, PhD; Alexandre R. Franco, PhD; R. Cameron Craddock, PhD; Helen S. Mayberg, MD

IMPORTANCE Currently, fewer than 40% of patients treated for major depressive disorder achieve remission with initial treatment. Identification of a biological marker that might improve these odds could have significant health and economic impact.

OBJECTIVE To identify a candidate neuroimaging “treatment-specific biomarker” that predicts differential outcome to either medication or psychotherapy.

DESIGN Brain glucose metabolism was measured with positron emission tomography prior to treatment randomization to either escitalopram oxalate or cognitive behavior therapy for 12 weeks. Patients who did not remit on completion of their phase 1 treatment were offered enrollment in phase 2 comprising an additional 12 weeks of treatment with combination escitalopram and cognitive behavior therapy.

SETTING Mood and anxiety disorders research program at an academic medical center.

PARTICIPANTS Men and women aged 18 to 60 years with currently untreated major depressive disorder.

INTERVENTION Randomized assignment to 12 weeks of treatment with either escitalopram oxalate (10-20 mg/d) or 16 sessions of manual-based cognitive behavior therapy.

MAIN OUTCOME AND MEASURE Remission, defined as a 17-item Hamilton Depression Rating Scale score of 7 or less at both weeks 10 and 12, as assessed by raters blinded to treatment.

RESULTS Positive and negative predictors of remission were identified with a 2-way analysis of variance treatment (escitalopram or cognitive behavior therapy) × outcome (remission or nonresponse) interaction. Of 65 protocol completers, 38 patients with clear outcomes and usable positron emission tomography scans were included in the primary analysis: 12 remitters to cognitive behavior therapy, 11 remitters to escitalopram, 9 nonresponders to cognitive behavior therapy, and 6 nonresponders to escitalopram. Six limbic and cortical regions were identified, with the right anterior insula showing the most robust discriminant properties across groups (effect size = 1.43). Insula hypometabolism (relative to whole-brain mean) was associated with remission to cognitive behavior therapy and poor response to escitalopram, while insula hypermetabolism was associated with remission to escitalopram and poor response to cognitive behavior therapy.

CONCLUSIONS AND RELEVANCE If verified with prospective testing, the insula metabolism-based treatment-specific biomarker defined in this study provides the first objective marker, to our knowledge, to guide initial treatment selection for depression.

TRIAL REGISTRATION Registered at clinicaltrials.gov (NCT00367341)

Major depressive disorder (MDD) is a highly prevalent, disabling, and costly illness. For a patient presenting with MDD, an antidepressant medication or evidence-based psychotherapy is currently recommended as first-line treatment. However, fewer than 40% of patients achieve remission with initial treatment, and choosing the “wrong” initial treatment has significant individual and societal costs due to continued distress, risk of suicide, loss of productivity, and wasted resources associated with 2 to 3 months of an ineffective treatment. Given the public health consequences of inadequately treated depression, a clinical or biological marker to guide initial treatment selection for MDD could have major health and economic impact.

In other areas of medicine, identification of markers to guide treatment has significantly improved clinical outcome. For example, in cancer and heart disease, biomarkers are currently used to optimize initial treatment selection as well as guide treatment modifications with disease progression. Over the past several decades, a number of potential markers to guide antidepressant treatment have been investigated including clinical, immune, inflammatory, endocrine, genetic, and imaging/electroencephalography measures. Despite this extensive research, to our knowledge, no prior imaging study has directly assessed whether pretreatment brain activity patterns can predict efficacy but those to 2 or more different treatments.

In the process of developing a marker to guide antidepressant treatment selection, it is important to consider what qualities such a marker should have. Toward this goal, a nonspecific biomarker that predicts improvement regardless of treatment is not useful. Rather, a clinically meaningful and treatment-specific biomarker (TSB) should (1) predict an individual’s improvement to a specific treatment and (2) predict nonresponse to an alternative treatment. Such a biomarker can only be identified in a study that assesses outcomes to 2 or more different treatments.

Previous neuroimaging studies have suggested that pretreatment brain activity patterns can predict efficacy, but those studies have generally focused on a particular treatment. For example, higher rostral cingulate and/or subgenual cingulate activity has been associated with greater improvement with antidepressant medications, sleep deprivation, and cingulotomy. Comparisons of different treatments have thus far identified markers of response and nonresponse but not patterns that differentiate among the treatments tested. Further, imaging studies demonstrate that medications and psychotherapy have differential effects on distinct brain regions, suggesting that baseline activity may indicate response to one treatment vs the other. Although, to our knowledge, no prior imaging study has directly assessed the association of pretreatment brain activity patterns with differential response to different treatments (eg, medication vs psychotherapy), these past studies strongly suggest that a neuroimaging-based TSB can be defined.

In this study, we measured pretreatment brain glucose metabolism in patients with MDD randomized to receive a selective serotonin reuptake inhibitor (escitalopram oxalate) or cognitive behavior therapy (CBT). Positron emission tomography (PET) scan measurement of glucose metabolism was selected based on its high reliability and availability combined with its established use for studies of baseline scan patterns in depression and effects of various antidepressant treatments. Our aim was to define an imaging TSB for these 2 potential first-line treatments, ie, a brain activity pattern that distinguishes escitalopram remitters from both escitalopram nonresponders and CBT remitters while concurrently distinguishing CBT remitters from both CBT nonresponders and escitalopram remitters.

Methods

Patient Selection

Written informed consent was obtained from all participants, with the protocol conducted as approved by the Emory institutional review board and registered at clinicaltrials.gov (NCT00367341). Eligible participants were adult outpatients with a primary diagnosis of MDD as assessed by the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen and confirmed through a psychiatric evaluation conducted by a study psychiatrist. Patients aged 18 to 60 years were recruited through the Mood and Anxiety Disorders Program at Emory University via advertisements and clinician referrals. Patients were required to have moderate to severe symptoms of depression, defined as a 17-item Hamilton Depression Rating Scale (HDRS) score of 18 or more at screening and 15 or more at the baseline randomization visit. Exclusion criteria included a current diagnosis of a primary psychiatric disorder other than MDD; a medical or neurological condition that could contribute to depression or that might interfere with response to treatment such as chronic pain syndromes and irritable bowel syndrome; current suicidal ideation requiring urgent clinical intervention; comorbid substance abuse within the past 3 months; substance dependence within 12 months prior to the screening visit; current or intended pregnancy or breastfeeding; use of antidepressants within 7 days of the screening visit (5 weeks for fluoxetine); current psychotherapy at the time of screening; or receipt of electroconvulsive therapy within 6 months of the screening visit. Patients were also excluded if they had a lifetime history of failure to respond to 6 or more weeks of treatment with escitalopram oxalate (≥10 mg/d) or 4 or more sessions of CBT for depression.

Treatment Protocol

Treatment consisted of 2 phases: a short-term treatment phase (phase 1) and a combination treatment phase (phase 2). Phase 1 provided the data for this report. In phase 1, patients were randomly assigned (1:1 ratio) to receive a 12-week treatment course of either escitalopram oxalate (flexibly dosed from 10-20 mg/d) or manual-based, depression-focused CBT (16 one-hour sessions over 12 weeks) (Figure 1). Prior to study start, the study statistician prepared a permuted-block randomization schedule, with the assignments placed in order and sealed in opaque envelopes. Following acquisition of the pretreatment PET and magnetic resonance imaging scans, patients who continued to meet eligibility criteria were randomized to escitalopram oxalate (flexibly dosed from 10-20 mg/d) or manual-based, depression-focused CBT (16 one-hour sessions over 12 weeks).
lopram or CBT. Escitalopram oxalate was started at 10 mg/d and could be increased to 20 mg/d or after week 3 if the patient had an HDRS score more than 7 and was tolerating the medication. Down-titration to 10 mg/d was permitted if adverse effects were intolerable at the 20–mg/d dose. The CBT sessions were scheduled twice weekly for the first 4 weeks, followed by weekly sessions for the subsequent 8 weeks. Changes in symptom severity were assessed using the HDRS conducted by raters blinded to treatment group. Ratings were performed weekly for the first 6 weeks and then biweekly until week 12. Patients who did not remit on completion of their phase 1 treatment were offered enrollment in phase 2 comprising an additional 12 weeks of treatment with combination escitalopram and CBT.

Outcome Metrics
Clinical outcomes were defined using the HDRS, with the target end point being remission, defined as an HDRS score of 7 or less at both weeks 10 and 12 of phase 1 treatment, to ensure stability of remission beyond a single “good week.” Nonresponse was defined as a 30% or less HDRS score change from baseline to the phase 1 end point. Partial responders (change in HDRS score >30% but not achieving remission) and dropouts were not included in the analyses for this report to avoid potential dilution of either the remission or the nonresponse groups.

Imaging Acquisition
Prior to treatment randomization, brain glucose metabolism was measured using PET (High-Resolution Research Tomograph scanner; Siemens), using standard methods without arterial blood sampling. For each scan, a 370-MBq dose of fludeoxyglucose F18 (FDG) was administered intravenously, with a 20-minute 3-dimensional image acquisition beginning 40 minutes after tracer injection. During uptake, patients remained supine, awake, and resting with eyes closed and ears uncovered. Patients were given no explicit cognitive instructions but were asked to avoid ruminating on any 1 topic during the 40-minute FDG uptake period. Raw emission images were corrected for injected dose and attenuation (using cesium137, 6-minute transmission scan), reconstructed, and smoothed to an in-plane resolution of 4.0 mm Full-Width Half-Maximum. A high-resolution T1-weighted structural magnetic resonance imaging scan was separately acquired for spatial normalization procedures and anatomical reference (TIM Trio 3-T whole-body scanner; Siemens) (3-dimensional magnetization-prepared rapid acquisition with gradient echo optimized at a tech time = 5 milliseconds, repetition time = 35 milliseconds, matrix = 256 × 208 × 196, and 1-mm isotropic resolution).

Image Preprocessing
Attenuation-corrected PET images were coregistered to corresponding T1-weighted magnetic resonance imaging anatomical images using a 6-df linear transform and subsequently written into standard space using a nonlinear transform calculated from the T1-weighted image (DARTEL and SPM8; Wellcome Trust Centre for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm/). Four patients had no anatomical scan and were normalized using a study-specific FDG template. Spatially normalized images were smoothed with an 8-mm Full-Width Half-Maximum Gaussian kernel and corrected for differences in whole-brain global mean activity. Relative glucose metabolic rates were used for all analyses.

Image Analysis
A 2-way analysis of variance (ANOVA) with treatment (escitalopram or CBT) and outcome (remission or nonresponse) was performed to identify a putative escitalopram/CBT remission TSB using the baseline pretreatment FDG-PET scans (analyses performed with AFNI [National Institute of Mental Health,
National Institutes of Health] and SPSS [IBM SPSS], statistical threshold \( P < .001 \) uncorrected, and a minimum cluster volume of 100 voxels, 0.34 mL. With this approach, a main effect of remission would identify brain regions associated with remission to treatment independent of randomization group, ie, a nonspecific biomarker. The treatment \( \times \) outcome interaction would identify brain regions where the CBT treatment effect (remission or nonresponse) was distinguished from the escitalopram treatment effect (remission or nonresponse). Average normalized glucose metabolism values were extracted from clusters identified by the ANOVA (mean cluster activity) for further analysis.

Post hoc analyses of the extracted regions from the ANOVA interaction were used to refine selection of a potential TSB pattern by examining the effect sizes of the group differences for each region. We defined a region as a true TSB if it differentiated both the remission and nonresponse differences (by treatment) and the escitalopram and CBT differences (by outcome); thus, there were 4 comparisons of interest to consider when evaluating each region of interest as a stratification tool for treatment recommendation. Given the limited sample size, we report these comparisons using effect size, rather than statistical significance, to quantify their actual potential use as an eventual TSB. The 2-group effect size can be interpreted as the difference in metabolic activity between specified groups in units of standard deviation. \( ^{51} \) Because each region had a different magnitude of glucose metabolic activity and variation, each individual value was standardized using a \( z \) score, with regional \( z \) score means plotted to illustrate the nature of the regional interaction effects. Because these data are already standardized to the level of variation, there are no “error bars” in the related graphs.

To further assess the generalizability of findings identified in this restricted analysis to the full sample of study completers, metabolic activity was correlated with percentage of change in HDRS score within each treatment group to determine if the putative biomarkers identified in the ANOVA showed the predicted general pattern in the full cohort of phase 1 treatment completers.

### Results

#### Clinical Effects

Eighty-two patients were randomized to treatment; however, 2 patients received a change in their psychiatric diagnosis during the trial, and they were not used in the analyses. This resulted in 41 randomized to CBT and 39 to escitalopram. Sixty-five patients completed phase 1; 63 of the completers (79% of the total sample) had baseline FDG-PET scans available for analysis. Phase 1 remission rates were similar for both treatments: CBT = 9 of 33 (27.3%) and escitalopram = 6 of 30 (20.0%) (Figure 1 and Table 1). Nonresponse rates were also similar for both treatments: CBT = 9 of 33 (27.3%) and escitalopram = 6 of 30 (20.0%). Thirty-eight patients with clear outcomes and usable PET scans were included in the primary analysis: 12 patients with CBT remission, 11 patients with escitalopram remission, 9 patients with CBT nonresponse, and 6 patients with escitalopram nonresponse. There were no statistical differences in age, sex, or demographic or illness characteristics between randomization groups (escitalopram vs CBT). There were also no baseline demographic differences among the treatment-specific phase 1 outcome groups (Table 1).

### Neuroimaging Results

#### Treatment \( \times \) Outcome ANOVA

There was no significant main effect of remission, ie, no treatment-nonspecific biomarker was identified. Significant treat-
ment × outcome interaction effects were demonstrated for 6 regions: right anterior insula, right inferior temporal cortex (Brodmann area [BA] 20), left amygdala, left premotor cortex (BA 6), right motor cortex (BA 4), and precuneus (BA 7) (Table 2 and Figure 2).

Post hoc Analyses of Extracted Regions of Interest
The average effect sizes of each region for the various contrasts are shown in Table 2 in order of cluster size from the ANOVA. This was used to rank the regions of interest in the order of their potential utility as a discriminator. Only the insula and precuneus showed differences larger than 1 SD in all 4 contrasts, with the insula showing the largest average difference across all 4 comparisons. These findings indicate that metabolic activity of the right anterior insula is the most viable TSB candidate (Table 2 and Figure 3). Further, the anterior insula was the only region that showed relative hypometabolism in 1 group (region/whole-brain mean <1.0) and hypermetabolism in the other (region/whole-brain mean >1.0), adding support for potential use as a treatment stratification tool.

Assessment of the Insula TSB Across the Full Sample
There was a significant correlation between baseline insula activity and percentage of change in HDRS scores in both the CBT and escitalopram groups. A positive correlation was shown for

### Table 2. Treatment by Outcome Interaction Results and Post hoc Analyses of Extracted Regions of Interest

<table>
<thead>
<tr>
<th>Region</th>
<th>MNI Coordinates, Peak</th>
<th>Cluster Size, Voxels</th>
<th>Effect Sizesb</th>
<th>Average Marginal ES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior insula</td>
<td>+30.0 +24.0 −13.5 R</td>
<td>529</td>
<td>1.69 1.17 1.52 1.33 1.43</td>
<td>1.43</td>
</tr>
<tr>
<td>Inferior temporal (BA 20)</td>
<td>+42.0 −33.0 −25.5 R</td>
<td>469</td>
<td>1.23 1.45 2.09 0.59 1.34</td>
<td>1.34</td>
</tr>
<tr>
<td>Amygdala</td>
<td>−27.0 −7.5 −27.0 L</td>
<td>233</td>
<td>0.98 1.61 1.89 0.69 1.29</td>
<td>1.29</td>
</tr>
<tr>
<td>Premotor (BA 6)</td>
<td>−27.0 +1.5 +58.5 L</td>
<td>233</td>
<td>1.40 1.03 1.75 0.68 1.22</td>
<td>1.22</td>
</tr>
<tr>
<td>Motor (BA 4)</td>
<td>+25.5 −27.0 +60.0 R</td>
<td>147</td>
<td>0.61 1.78 1.80 0.58 1.19</td>
<td>1.19</td>
</tr>
<tr>
<td>Precuneus (BA 7)</td>
<td>−18.0 −67.5 +43.5 L</td>
<td>101</td>
<td>1.18 1.27 1.37 1.08 1.23</td>
<td>1.23</td>
</tr>
</tbody>
</table>

Abbreviations: BA, Brodmann area; CBT, cognitive behavior therapy; CBT–sCIT, mean difference between CBT and escitalopram oxalate (treatment effect); MNI, Montreal Neurological Institute; NR, nonresponders; REM, remitters; REM−NR, mean difference between remitters and nonresponders (remission effect); sCIT: escitalopram oxalate.

a Whole-brain 2-way analysis of variance with \( P < .001 \) uncorrected; voxel size, 1.5 mm × 1.5 mm × 1.5 mm.

b Effect size = mean difference divided by pooled standard deviation.

Figure 2. Potential Treatment-Specific Biomarker Candidates
Mean regional activity values for remitters and nonresponders segregated by treatment arm are plotted for the 6 regions showing a significant treatment × outcome analysis of variance interaction effect. Regional metabolic activity values are displayed as region/whole-brain metabolism converted to \( z \) scores. Regions match those shown in Table 2. Escitalopram was given as escitalopram oxalate. CBT indicates cognitive behavior therapy.
Among the 6 identified cortical and limbic regions, the anterior insula activity is linked to behaviors relevant to depression including interoception, emotional self-awareness, decision making, and cognitive control. The anterior insula is extensively connected to various frontal, limbic, and brainstem regions, including the anterior cingulate cortex, amygdala, and hypothalamus. Volume reductions of the anterior but not posterior insula have been described in currently ill patients with MDD as well as patients with remitted MDD compared with healthy controls. Changes in insula activity occur with a variety of treatments for MDD, including medication, vagus nerve stimulation, deep brain stimulation, and mindfulness training, suggesting a role for this region in mediating antidepressant response and remission more generally. Notably, past studies have reported both increases and decreases in baseline resting-state activity relative to never-depressed control subjects. This is consistent with the presence of at least 2 baseline patterns within the broader population of depressed patients. Most recently, baseline insula activity has been correlated with response to vagus nerve stimulation. These previous studies taken together with the current findings support the anterior insula as a potential candidate for imaging TSB.

Contrary to past published studies, the rostral anterior cingulate did not discriminate the outcome subgroups in either the main effect or interaction analyses. A post hoc examination of responder and nonresponder differences within each treatment arm did reveal a nonsignificant rostral cingulate activity difference, with metabolism in responders greater than nonresponders, but solely in the escitalopram group. While consistent with past reports, this finding did not meet the TSB criteria defined for the current study, ie, a region whose activity can differentiate both good and poor outcomes for both treatments.

Critical to the stated aims, remission (rather than response) was the targeted end point in this study because the presence of residual symptoms is a known predictor of clinical relapse, even in patients with significant improvement. Because the primary aim of this study was to identify distinct biomarker candidate...
Treatment-Specific Biomarker for Major Depression

Original Investigation Research

Brain patterns that optimally predict remission to each of 2 specific treatments, patients with unclear treatment outcomes were excluded from the primary analysis (ie, responders without remission and partial responders). This enriched sample allowed for detection of clear remission and nonresponse signals; as such, these analyses did not attempt to characterize the neurobiological variability of patients with more ambiguous clinical outcomes. This is a commonly used approach when the goal is to develop or test a biological signal for stratifying subjects.66,67 Nevertheless, baseline insula activity did correlate significantly with change in depression severity across all subjects, supporting the interpretation that insula activity is a plausible TSB suitable for further testing. Based on the correlational analysis across all subjects, the data further suggest that the anterior insula TSB may most optimally identify those patients who require CBT.

If confirmed with prospective testing, this putative TSB has both clinical and pathophysiological implications. At present, treatment failure with antidepressant medication often leads to the addition of a second drug and not a categorical switch to an evidence-based psychotherapy.68 Results herein suggest that patients who require CBT have a distinct neurophysiology that differs categorically from patients who require escitalopram and knowledge of such may help to improve current clinical practices. Further, using this or any other imaging-based TSB to define patient subgroups provides a brain-based platform to investigate genetic, immune, neuroendocrine, and behavioral variations from a new perspective.

While these first results are encouraging, there are several limitations. Clearly, there are patients who are not successfully treated with either of these 2 options, either alone or in combination.69 Therefore, our strategy can be best seen as a first-line stratification approach to treatment selection. Future studies, in addition to testing this insula biomarker prospectively, should include a design that works to identify patients resistant to both of these first-line treatments.50,70

The lack of a placebo arm could be considered a limitation, but given the randomized design of the study, there is no reason to believe that placebo respondents would be unevenly distributed between the 2 groups. Thus, even if present, placebo effects on remission rates would be expected to be similar in both treatment groups. Although inclusion of a placebo arm might have provided further insights into mediators of improvement during treatment, the absence of a placebo arm does not diminish the potential clinical utility of the identified TSB.

It is also possible that these results are specific to the cohort recruited for this trial. As such, a stratification strategy based on insula metabolism will require prospective testing in a new group of comparably depressed patients. Similarly, additional studies will be required to determine if remitters to other medications have a similar or different TSB from that seen with escitalopram or if remitters to other evidence-based psychotherapies have a similar TSB to that seen with CBT.71,72 Such studies are critical next steps toward the development of biology-based algorithms to guide treatment selection for MDD at all stages of illness. Still, if replicated, the insula TSB defined in this study would provide the first objective marker to guide initial treatment selection for major depression, an important advance in potentially reducing the costs and disability associated with this highly prevalent disorder.

ARTICLE INFORMATION
Submitted for Publication: August 29, 2012; final revision received January 11, 2013; accepted January 14, 2013.
Published Online: June 12, 2013. doi:10.1001/jamapsychiatry.2013.143.

Author Affiliations: Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia (McGrath, Dunlop, Croghan, Mayberg); Graduate Division of Biologic and Biomedical Sciences, Emory University, Atlanta, Georgia (McGrath); Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia (Kelley); Department of Neurology, Emory University, Atlanta, Georgia (Mayberg); Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire (Holtzheimer); Department of Electrical Engineering and Brain Institute, Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil (Franco); Center for the Developing Brain, Child Mind Institute, New York, New York (Cradock); Nathan Kline Institute for Psychiatric Research, Orangeburg, New York (Cradock).

Author Contributions: Dr Mayberg had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Disclosures: Dr Dunlop has received honoraria for consulting work performed for Bristol-Myers Squibb, MedAvante, Pfizer, and Roche. He has received research support from AstraZeneca, Bristol-Myers Squibb, Evotec, Forest, GlaxoSmithKline, Novartis, Ono Pharmaceuticals, Pfizer, Shire, Takeda, and Transcend. Dr Holtzheimer has received consulting fees from St Jude Medical Neuronomulation and Cervel Neurotech and an honorarium from Johnson & Johnson. Dr Croghan is a board member of Hugarheill, an Icelandic company dedicated to the prevention of depression, and he receives book royalties from John Wiley & Sons. He is a consultant to the George West Mental Health Foundation that oversees Skyland Trail, a residential treatment facility in Atlanta, Georgia. Dr Mayberg has received consulting and intellectual property licensing fees from St Jude Medical Inc.

Funding/Support: This work was supported by National Institutes of Health grants R01 MH073719 (Dr Mayberg), T32 GM08695 (Ms McGrath), K23 MH086690 (Dr Dunlop), and K23 MH077869 (Dr Holtzheimer).

Additional Contributions: Treating psychiatrists: Sheethal Reddy, PhD, Patrick Sylvers, PhD, Lorie Ritschel, PhD, Meredith Jones, PhD, Mary Heekin, LCSW, Maryrose Gerardi, PhD, and Jill Rosenberg, LCSW. Treating physicians: Ebram Haroon, MD, Jeffrey Rakofsky, MD, Dylan Wint, MD, and Corey Beck, MD. Clinical coordinators: Ronald Chismar, RN, Melanie Galanti, BA, Rachelle Gibson, RN, Lauren Marx, BS, Melissa McKenzie, BA, and Tanja Mletzko, MA. Imaging team: Rebecca DeMayo, MA, Eundria Hill, MSW, Kiseung Choi, MS, and Justin Rajendra, BA. Rateers: Margo Aaron, BA, Yara Betancourt, BA, Cristina Velasquez Delgado, BA, Novall Khan, BS, Ximena Marinic, BS, and Christopher Vaughan, BA.

REFERENCES
5. Kennedy SH, Lam RW, Parish SV, Patton SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANNAT) clinical guidelines for the management of major depressive disorder.


